Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
Alentis Therapeutics and PinotBio have signed a research and licensing agreement to develop new claudin-1-targeting antibody-drug conjugates. The partnership adds linker and payload options to a pipeline already containing two clinical-stage ADCs, although financial terms and new product candidates remain undisclosed.
Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.
Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.
Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!
Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.